Patents by Inventor Stewart Noble
Stewart Noble has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040242609Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 15, 2004Publication date: December 2, 2004Applicant: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, John Wetzel, John E. Deleon, Bharat Lagu, Charles Gluchowski, Stewart Noble, Dhanapalan Nagarathnam
-
Publication number: 20040106623Abstract: This invention is directed towards a method of inhibiting activation of a human &agr;1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human &agr;1d adrenergic receptor. This invention provides for a compound which binds selectively to a human &agr;1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human &agr;1d adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.Type: ApplicationFiled: November 20, 2003Publication date: June 3, 2004Applicant: Synaptic Pharmaceutical CorporationInventors: Michael Konkel, John M. Wetzel, Stewart A. Noble, Charles Gluchowski, Douglas A. Craig
-
Patent number: 6720324Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject.Type: GrantFiled: July 5, 2001Date of Patent: April 13, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, John Wetzel, John E. DeLeon, Bharat Lagu, Charles Gluchowski, Stewart Noble, Dhanapalan Nagarathnam
-
Patent number: 6706716Abstract: This invention is directed towards a method of inhibiting activation of a human &agr;1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human &agr;1d adrenergic receptor. This invention provides for a compound which binds selectively to a human &agr;1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human &agr;1d adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.Type: GrantFiled: January 17, 2001Date of Patent: March 16, 2004Assignee: Synaptic Pharmaceutical CorporationInventors: Michael Konkel, John M. Wetzel, Stewart A. Noble, Charles Gluchowski, Douglas A. Craig
-
Publication number: 20030176314Abstract: This invention provides methods of treating pain, urinary incontinence and other abnormalities mediated by a NPFF receptor, which comprises administering to a subject a therapeutically effective amount of a chemical compound which acts at the NPFF1 receptor, the NPFF2 receptor, or at both the NPFF1 and NPFF2 receptors.Type: ApplicationFiled: September 24, 2002Publication date: September 18, 2003Inventors: Carlos C. Forray, Joel Kawakami, Michael J. Konkel, Lakmal W. Boteju, John M. Wetzel, Stewart A. Noble, Honghe Wan
-
Publication number: 20030139431Abstract: This invention provides compounds having the structure: 1Type: ApplicationFiled: September 21, 2002Publication date: July 24, 2003Inventors: Joel K. Kawakami, John Wetzel, Lakmal W. Boteju, Michael J. Konkel, Honghe Wan, Stewart A. Noble
-
Patent number: 6569856Abstract: This invention is directed to triazine derivatives which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: January 3, 2002Date of Patent: May 27, 2003Assignee: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, Stewart A. Noble, Mahesh N. Desai
-
Publication number: 20030069261Abstract: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 5, 2001Publication date: April 10, 2003Inventors: Mohammad R. Marzabadi, John Wetzel, John E. DeLeon, Bharat Lagu, Charles Gluchowski, Stewart Noble, Dhanapalan Nagarathnam
-
Publication number: 20020103201Abstract: This invention is directed to triazine derivatives which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: ApplicationFiled: January 3, 2002Publication date: August 1, 2002Applicant: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, Stewart A. Noble, Mahesh N. Desai
-
Publication number: 20020028760Abstract: This invention is directed towards a method of inhibiting activation of a human &agr;1d adrenergic receptor which comprises contacting the receptor with a compound so as to inhibit activation of the receptor, wherein the compound binds selectively to a human ald adrenergic receptor. This invention provides for a compound which binds selectively to a human &agr;1d adrenergic receptor. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier. This invention further provides for a method of treating a subject afflicted with a disease which is susceptible to treatment by antagonism of the human &agr;1d adrenergic receptor which comprises administering to the subject an amount of the above defined compounds effective to treat the disease.Type: ApplicationFiled: January 17, 2001Publication date: March 7, 2002Inventors: Michael Konkel, John M. Wetzel, Stewart A. Noble, Charles Gluchowski, Douglas A. Craig
-
Patent number: 6340683Abstract: This invention is directed to triazine derivatives which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: April 22, 1999Date of Patent: January 22, 2002Assignee: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, Stewart A. Noble, Mahesh N. Desai
-
Patent number: 6225330Abstract: This invention is directed to tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: June 30, 1999Date of Patent: May 1, 2001Assignees: Synaptic Pharmaceutical Corporation, Novartis AGInventors: Mohammad R. Marzabadi, Wai C. Wong, Walter Schilling, Stewart A. Noble
-
Patent number: 6222040Abstract: This invention is directed to tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: June 30, 1999Date of Patent: April 24, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, Peter Bühlmayer, Heinrich Rüeger, Wai C. Wong, Yasuchika Yamaguchi, Stewart A. Noble
-
Patent number: 6218408Abstract: This invention is directed to bicyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: June 30, 1999Date of Patent: April 17, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, Wai C. Wong, Stewart A. Noble
-
Patent number: 6214853Abstract: This invention is directed to bicyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: June 30, 1999Date of Patent: April 10, 2001Assignee: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, Wai C. Wong, Yasuchika Yamaguchi, Stewart A. Noble
-
Patent number: 6124331Abstract: This invention is directed to tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.Type: GrantFiled: June 30, 1999Date of Patent: September 26, 2000Assignee: Synaptic Pharmaceutical CorporationInventors: Mohammad R. Marzabadi, Wai C. Wong, Stewart A. Noble
-
Patent number: 4383990Abstract: The compound of formula (I): ##STR1## wherein X is CFCl; and C.sub.1-6 alkanoyl esters and/or phosphate esters thereof, is active against herpes viruses.Type: GrantFiled: September 21, 1981Date of Patent: May 17, 1983Assignee: Beecham Group LimitedInventors: Paul L. Coe, Albert S. Jones, Stewart A. Noble, Richard T. Walker